ArticleCellular & molecular biology letters2025
Human umbilical cord mesenchymal stromal cell-derived exosomes alleviate antibiotic-induced intestinal barrier damage by regulating autophagy via the S100G/mTOR signaling pathway.
Article in Cellular & molecular biology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Application of Human Umbilical Cord Mesenchymal Stem Cells and Their Derived Exosomes in Gastrointestinal Diseases.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundAntibiotics are a double-edged sword. Long-term, broad-spectrum, and high-dose antibiotic use can lead to the occurrence of related diseases, particularly attracting attention in the context of intestinal barrier damage. However, current clinical treatments remain suboptimal. Human umbilical cord mesenchymal stromal/stem cell-derived exosomes (HucMSCs-Exo) have demonstrated therapeutic efficacy in tissue repair and inflammatory bowel diseases. However, studies on their role in antibiotic-induced intestinal barrier damage remain limited.
objectiveThis study aims to investigate the therapeutic effects and underlying mechanisms of HucMSCs-Exo in treating antibiotic-induced intestinal mucosal barrier damage.
methodsA mouse model of antibiotic-induced intestinal barrier damage was established by administering clindamycin hydrochloride via gavage for 28 consecutive days in C57BL/6 male mice. The therapeutic effects of HucMSCs-Exo were evaluated through intraperitoneal injections at low and high concentrations every other day. Transcriptomic sequencing and other techniques were used to identify target genes and mechanistic pathways involved in HucMSCs-Exo mediated repair of intestinal mucosal barrier damage. Finally, the findings were validated in vitro using human colonic epithelial NCM460 cells.
resultsThe in vivo mouse experiments demonstrated that HucMSCs-Exo effectively alleviated antibiotic-induced intestinal barrier damage. Both low- and high-concentration exosome treatments improved the antibiotic-induced reduction in body weight gain, shortened colon length,disrupted intestinal epithelial continuity, increased permeability owing to microvilli structural damage, and decreased expression of tight junction proteins (ZO-1, Occludin, and Claudin-1). The in vitro cell experiments further showed that both low- and high-concentration exosome treatments restored antibiotic-induced reductions in cell proliferation and migration, as well as increased autophagy and apoptosis, with the high-concentration group showing significant differences (p < 0.05). Transcriptomic analysis of mouse colonic tissues revealed that differentially expressed genes were enriched in autophagy-related and apoptosis-related pathways, with S100G identified as a potential target gene of HucMSCs-Exo. Knockdown of the S100G gene in NCM460 cells yielded results consistent with the HucMSCs-Exo treatment group, indicating that HucMSCs-Exo exerts its effects by promoting mTOR phosphorylation, thereby inhibiting excessive autophagy.
conclusionsHucMSCs-Exo alleviates antibiotic-induced intestinal mucosal barrier damage by inhibiting excessive autophagy-mediated apoptosis via the S100G/mTOR signaling pathway. Our findings elucidate the role and mechanism of exosomes in antibiotic-induced intestinal mucosal barrier damage, providing new insights for the therapeutic potential of exosomes in related fields.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.